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Abstract
Background: Bone morphogenetic proteins (BMPs) are key regulators in the embryonic development and postnatal
tissue homeostasis in all animals. Loss of function or dysregulation of BMPs results in severe diseases or even lethality.
Like transforming growth factors β (TGF-βs), activins, growth and differentiation factors (GDFs) and other members of
the TGF-β superfamily, BMPs signal by assembling two types of serine/threonine-kinase receptor chains to form a hetero-
oligomeric ligand-receptor complex. BMP ligand receptor interaction is highly promiscuous, i.e. BMPs bind more than
one receptor of each subtype, and a receptor bind various ligands. The activin type II receptors are of particular interest,
since they bind a large number of diverse ligands. In addition they act as high-affinity receptors for activins but are also
low-affinity receptors for BMPs. ActR-II and ActR-IIB therefore represent an interesting example how affinity and
specificity might be generated in a promiscuous background.
Results: Here we present the high-resolution structures of the ternary complexes of wildtype and a variant BMP-2
bound to its high-affinity type I receptor BMPR-IA and its low-affinity type II receptor ActR-IIB and compare them with
the known structures of binary and ternary ligand-receptor complexes of BMP-2. In contrast to activin or TGF-β3 no
changes in the dimer architecture of the BMP-2 ligand occur upon complex formation. Functional analysis of the ActR-
IIB binding epitope shows that hydrophobic interactions dominate in low-affinity binding of BMPs; polar interactions
contribute only little to binding affinity. However, a conserved H-bond in the center of the type II ligand-receptor
interface, which does not contribute to binding in the BMP-2 – ActR-IIB interaction can be mutationally activated
resulting in a BMP-2 variant with high-affinity for ActR-IIB. Further mutagenesis studies were performed to elucidate the
binding mechanism allowing us to construct BMP-2 variants with defined type II receptor binding properties.
Conclusion: Binding specificity of BMP-2 for its three type II receptors BMPR-II, Act-RII and ActR-IIB is encoded on
single amino acid level. Exchange of only one or two residues results in BMP-2 variants with a dramatically altered type
II receptor specificity profile, possibly allowing construction of BMP-2 variants that address a single type II receptor. The
structure-/function studies presented here revealed a new mechanism, in which the energy contribution of a conserved
H-bond is modulated by surrounding intramolecular interactions to achieve a switch between low- and high-affinity
binding.
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Background
Bone morphogenetic proteins (BMPs) and other mem-
bers of the transforming growth factor-β (TGF-β) super-
family, like the activins, growth and differentiation factors
(GDFs) and TGF-βs are secreted signaling proteins that
regulate the development, maintenance and regeneration
of tissues and organs [1-4]. Their importance in the devel-
opment of multicellular organisms is visible from their
existence in all vertebrates and non-vertebrate animals.
The number of different TGF-β members correlates with
the complexity of the organism, with four members found
in C. elegans [5], seven members in D. melanogaster [6] and
more than 30 members in men [7]. Dysregulation of sig-
naling of TGF-β like proteins leads to a variety of diseases,
including skeletal malformations [8], osteoporosis [9],
cardiovascular and metabolic diseases [10], muscular dis-
orders [11], and cancer [12].
Members of the TGF-β superfamily bind two different
types of serine/threonine-kinase receptors termed type I
and type II receptors [2,13,14]. Both receptor subtypes
share a common architecture, i.e. a small extracellular lig-
and binding domain, a single transmembrane segment
and a cytoplasmic serine/threonine-kinase domain. The
kinase domains of type I and type II receptors share a high
level of amino acid sequence similarity. However a gly-
cine/serine-rich segment – the GS box – in the membrane-
proximal part of the intracellular domain is unique to the
type I receptors. In general, ligand binding induces hetero-
oligomerization of type I and type II receptors initiating
the intracellular signaling cascade. The constitutively
active type II serine/threonine-kinase transphosphorylates
the type I receptor at the GS box thereby activating the
type I kinase [15]. The latter subsequently activates SMAD
proteins, which dimerize and migrate to the nucleus,
where they, in concert with other proteins, function as
transcription factors to regulate responsive genes [16,17].
Two SMAD pathways exist. SMAD-2/-3 are activated by
activins and TGF-βs and SMAD-1/-5/-8 are activated by
BMPs and a subset of GDFs. Recent discoveries however
show that other signaling pathways involving the MAP
kinase pathway or small G proteins like Ras might be
directly addressed by TGF-β members [18]. Proteomics
approaches also identified various adaptor and other pro-
teins associated with the intracellular domain of the BMP
type II receptor suggesting that signaling of TGF-βs and
BMPs might be more complex than the well-examined
SMAD pathway [19].
Signal transduction of TGF-β proteins is highly controlled
at several levels; a manifold of modulator proteins in the
extracellular space vary the activities of these factors [20].
Although they are often termed antagonists there are also
examples of modulator proteins leading to an increase in
receptor-mediated activity [21]. Pseudo receptors as well
as co-receptors can either inhibit or modulate signaling at
the membrane surface level [22,23]. Inside the cell various
possibilities exist to adjust or interrupt the activity, e.g. by
inhibitory SMAD proteins, phosphatases to counteract the
receptor kinase activity [24], ubiquitination-dependent
proteolysis of the receptors/SMADs [25,26] or by tran-
scriptional repressors [27].
One important feature of the TGF-β superfamily is the
limited specificity of its ligand-receptor interactions. For
more than 30 ligands only seven type I receptors and five
type II receptors are known. Thus one receptor of a partic-
ular subtype has to bind several different ligands. But even
though the ligands outnumber the available receptors,
several BMPs and GDFs have been shown to interact with
several different receptor chains of both type I and type II.
However, preferences seem to exist. For instance BMP-2
uses preferentially BMPR-IA and BMPR-IB less so [28],
GDF-5 prefers BMPR-IB [29] and BMP-7 ActR-I [30]. An
especially intriguing situation exists with the type II
activin receptors ActR-II and ActR-IIB which interact with
different BMPs, activins, GDF-8/-11 and Nodal [15,31].
Ligand specific patterns seem to exist for type I and type II
receptors. Recent clinical and biochemical studies on
GDF-5 have shown that the receptor specificity profile of
a ligand can be absolutely crucial for its biological func-
tions [32,33]. This underlines the importance of under-
standing the molecular mechanisms by which these
relative binding affinities are generated.
In the present study we analyze the interaction of BMP-2
with its type I receptor BMPR-IA and its type II receptor
ActR-IIB. BMP-2 is a prototypical member of the TGF-β
superfamily with respect to ligand-receptor promiscuity. It
binds with high-affinity to both type I receptors BMPR-IA
and BMPR-IB; three different type II receptors, i.e. BMPR-
II, ActR-II and ActR-IIB can be recruited to yield a signal-
ing hetero-oligomeric complex [15,34]. The usage of the
activin type II receptors is especially interesting as they
exhibit a dual specificity and affinity [29,30,35,36]. ActR-
II and ActR-IIB bind activin A (Act-A) with high affinity in
the low nanomolar range leading to activation of the
SMAD-2/-3 pathway, whereas binding of BMP-2 occurs
with low-affinity in the micromolar range resulting in the
activation of the SMAD-1/-5/-8 pathway. Since Act-A and
BMPs can exhibit opposing activities [37,38], which are
regulated by competition for the activin type II receptors,
it is important to know how the binding affinity to both
ligand subgroups activins and BMPs can be changed by
orders of magnitude.
Here we describe in a structure-/function analysis how
binding specificity of the type II receptor ActR-IIB for dif-
ferent ligands as well as of BMP-2 for different type II
receptors is encoded on a single-amino acid level. A singleBMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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mutation in BMP-2 selectively enhances the binding affin-
ity for BMPR-II. Exchange of two other amino acids results
in a nearly 100-fold increase in affinity particular for type
II receptor ActR-IIB without affecting the binding affinities
to the other receptors. Remarkably, a "silent H-bond" is
thereby converted into a hot spot of binding energy,
which also exists in Act-A.
Results
Architecture and assembly of the ternary ligand-receptor 
complex
The crystal structure of the ternary ligand-receptor com-
plex of wildtype BMP-2 shows a dimeric ligand bound to
only one BMPR-IAECD  and ActR-IIBECD  occupying the
expected wrist (type I receptor binding site) and knuckle
epitopes (type II receptor binding site). Both receptor
ectodomains are located on the same half of the dimeric
ligand (Fig. 1), with the binding sites being almost identi-
cal to those identified in the crystal structures of the com-
plexes BMP-2:BMPR-IA [39] and BMP-7:ActR-II [40]. The
change in ligand-receptor stoichiometry in the crystal is
clearly due to crystal packing as SDS-PAGE and RP-HPLC
analyses proved this complex to be hexameric in solution
(see Additional file 1). Inspection of the crystal lattice con-
tacts shows that symmetry-related proteins block the
empty epitopes.
Ternary ligand-receptor complex of wildtype BMP-2 Figure 1
Ternary ligand-receptor complex of wildtype BMP-2. Ribbon representation (stereo figure) of the crystal structure of 
wildtype BMP-2 (monomers in yellow and blue) bound to one receptor ectodomain of BMPR-IAECD (green) and ActR-IIBECD 
(red), (a) viewed from the side, (b) or from above. The unexpected stoichiometry 1:1:1 is due to crystal packing forces result-
ing in the loss of one BMPR-IAECD and one ActR-IIBECD molecule in the ternary complex.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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In a second analysis a BMP-2 variant with enhanced affin-
ity for ActR-IIB (see below) was used for complex prepara-
tion and crystallization. Crystals from this complex
comprising the BMP-2 variant L100K/N102D were
obtained under different crystallization conditions and
exhibit distinct morphology. Analysis of this complex
yielded a hexameric ligand-receptor arrangement with all
receptor binding epitopes occupied as expected for the
dimeric BMP-2 (Fig. 2a,b).
Inspection of the receptor-ligand interactions of both
BMP-2/receptor complexes (comprising BMP-2 L100K/
N102D, in the following termed ternary complex (1:2:2),
or wildtype BMP-2, in the following termed ternary com-
plex (1:1:1)) demonstrates that the ligand-receptor inter-
faces are highly similar. Superposition of the complexes
yields an r.m.s. deviation of 0.3 Å for the Cα atoms of
BMP-2 (in the ternary complex (1:1:1) only "bound" parts
of BMP-2 were considered), and 0.4 Å for the Cα of BMP-
2 and ActR-IIBECD (see Additional file 2). Thus, the differ-
ent crystal forms and the employed mutant protein did
not alter the general fold or the assembly of BMP-2 and
the receptors. This indicates that the core parts of these
proteins are rigid and that no major conformational
changes take place during complex formation.
The type I receptor BMPR-IAECD occupies the wrist epitope
of BMP-2 (Figs. 1 and 2a,b), whereas the type II receptor
ActR-IIBECD is located on top of finger 1 of BMP-2 consist-
ent with the knuckle epitope identified by mutagenesis
[28,39]. This binding site overlaps almost perfectly with
that of ActR-IIB in the structures of the Act-A:(ActR-IIB-
ECD)2 complex [41,42]. A comparison with the ActR-II
binding site in the structure of the complex BMP-7:(ActR-
IIECD)2 [40] shows that the site of ActR-II however is
shifted slightly away from the fingertips. In the recently
published structure of another BMP-2 ternary ligand-
receptor complex comprising of BMPR-IAECD and ActR-
IIECD [43], the binding site of ActR-II is, however, identical
with that of ActR-IIB in our complex structures. This
observation suggests that the type II receptor location in
the knuckle epitope is probably dependent on the nature
of the ligand, here BMP-2 or BMP-7. The slight shift of the
epitope might represent one possible mechanism for gen-
erating ligand specific receptor recognition.
In contrast, in other TGF-β ligand-receptor complexes, e.g.
Act-A:ActR-IIBECD and TGF-β3:TβR-II, the ligand structures
differ vastly in the free and bound form [41,42,44,45].
The cause for the large changes in the dimer architecture
of Act-A and TGF-βs is yet unclear, but is probably not due
to receptor binding itself. Inspection of the backbone
dynamics in TGF-β3 using NMR-relaxation methods
reveals an inherent flexibility in the TGF-β molecule [46],
which might result in an dynamic equilibrium between an
open and a closed dimer architecture for TGF-βs and pos-
sibly also activins [47]. In contrast, BMP-2 seems not to
change its overall dimer architecture upon binding to
either type I or both receptor subtypes. Accordingly, in the
absence of gross conformational changes binding affini-
ties of ActR-IIB for BMP-2 alone or for BMP-2 complexed
with BMPR-IAECD are identical (see Additional file 3). Our
current structural data also excludes the possibility that
the binding cooperativity for the type II receptor observed
for BMP-2 in cell-based experiments [2] results from direct
contacts between the receptor ectodomains as proposed
for the TGF-βs [44,47]. The closest proximity between the
ectodomains of either subtype measures about 12 Å (Fig.
2c,d). Involvement of the intracellular domains of the
receptors in the generation of binding cooperativity has
been ruled out by binding experiments using truncated
receptors [40].
An alternative model suggests interaction of the trans-
membrane segments as a possible source for cooperativ-
ity. However, the distance between the C-termini of both
ActR-IIBECD (Fig. 2c) is about 85 Å and the C-termini of
BMPR-IAECD are separated by approx. 70 Å. The distance
between the traceable C-termini of the receptor ectodo-
mains BMPR-IA and ActR-IIB measures about 40 Å. Mod-
eling of the missing C-terminal peptide sequences – no
electron density is observed for the six C-terminal residues
of BMPR-IAECD and 20 residues of ActR-IIBECD – shows
that contacts between all four transmembrane helices are
impossible due to steric restraints by the ligand. Only het-
ero-dimeric interactions between the transmembrane hel-
ices of one BMPR-IA and one ActR-IIB receptor residing
on the same half of the BMP-2 ligand are possible (see
also discussion in Allendorph et al. [43]).
Ternary complex formation does not alter type I ligand-
receptor core interface
Although the global fold of BMP-2 is not affected by the
binding of both receptor subtypes, small locally restricted
changes in backbone and side chain conformations are
observed in the wrist and knuckle epitopes of both ternary
complexes. The binding of BMP-2 to its high-affinity
receptor BMPR-IAECD causes a local induced fit in the so-
called pre-helix segment (Pro48-Asn56) of BMP-2 [48]. In
free BMP-2 this segment exhibits high temperature factors
but upon type I receptor binding temperature factors
within this segment drop to low values also observed in
the core of the binary complex BMP-2:BMPR-IAECD.
Interestingly, binding of ActR-IIB to the binary complex
BMP-2:BMPR-IAECD results in a small but significant reo-
rientation of BMPR-IA. This reorientation is identical in
both ternary complexes, comprising wildtype BMP-2 as
well as the double variant BMP-2L100K/N102D. Thus the
allosteric change in the assembly is neither dependent onBMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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Ternary ligand-receptor complex of BMP-2 variant L100K/N102D Figure 2
Ternary ligand-receptor complex of BMP-2 variant L100K/N102D. Ribbon representation (stereoview) of the ternary 
complex of the BMP-2 double variant L100K/N102D (in yellow and blue) bound to BMPR-IAECD (green) and ActR-IIBECD (red), 
viewed from the side (a) or from above (b). (c) Distances between the C-termini of the receptor ectodomains of each sub-
type are indicated. (d) The shortest distance between BMPR-IAECD and ActR-IIBECD occurs between the two receptor ectodo-
mains located on the same half of the BMP-2 dimer across the β-sheet of BMP-2 and measures ~12 Å. No direct receptor-
receptor contacts between the ectodomains of either subtype as proposed for the TGF-β:TGF-β receptor interaction [44, 47, 
61] can be observed.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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the stoichiometry nor on the difference in affinity to the
type II receptor ActR-IIB. The BMPR-IA molecule changes
its tilt angle by about 8° compared to the binary complex
of BMPR-IA bound to BMP-2 (Fig. 3a). The axis of rotation
runs through the type I interface core, i.e. residue Gln86 of
BMPR-IA, perpendicular to the dyad of the complex. The
movement of BMPR-IA seems to be initiated by small
structural changes in the backbone conformation of resi-
dues 86 to 88 and 100 to 105 in the β-strands 6 and 7 of
finger 2 of BMP-2. Both strands move towards ActR-IIB up
to 1.5 Å and this change seems to be propagated to the
wrist epitope (Fig. 3b). The structure of BMPR-IA remains
unaltered and the BMP-2 molecule is therefore the sole
source of the observed structural plasticity. As a result, res-
idues located far from the axis of rotation show the largest
displacement, e.g. residues in the loops β1β2 and β3β4 of
BMPR-IA move by almost 4 Å (Fig. 3a). In contrast, resi-
dues in the type I ligand-receptor interface core are not
affected; nine intermolecular hydrogen bonds (H-bonds)
observed in the core of the wrist epitope of BMP-2 and
BMPR-IAECD of the binary complex are also found in both
ternary complexes (Fig. 3c,d, see Additional file 4) and
their geometrical parameters (e.g. hydrogen bond length
and angles) are preserved.
For the recently published structure of the ternary ligand-
receptor complex of BMP-2 bound to BMPR-IA and ActR-
II, no such rearrangement for the type I receptor binding
has been described [43]. A detailed comparison of this
complex structure with those of this study reveals that the
change in type I receptor orientation is significantly
smaller; the tilt angle of BMPR-IA changes by only 3°
compared to its location in the BMP-2:BMPR-IAECD binary
complex. Consistently, the change in backbone confor-
mation of the β-strands 6 and 7 of BMP-2 in the complex
of Allendorph et al. is also smaller, e.g. the distance
between the Cα atoms of Asn102 of the binary and ter-
nary complex is 1 Å (for comparison the distance between
the Cα atoms of Asn102 of the binary complex and the
ternary complexes of this study is roughly 2 Å, see Fig. 3b).
Although the physiological role of the type I receptor rear-
rangement is yet unknown – our BIAcore study clearly
shows that type II receptor ectodomain binding to BMP-2
is independent of the presence of a type I receptor – the
comparison suggests that the different change in type I
receptor orientation might be dependent on the nature of
the type II receptor.
Analysis of solvent molecules in the BMP-2 type I receptor
interface has shown that the main-binding determinants
of the BMP-2 – type I receptor interaction are surrounded
by tightly bound water molecules, which seem to play an
important role in the ligand-receptor recognition mecha-
nism. Of these water molecules in the type I receptor-lig-
and interface of the binary complex [48], all (four in the
core, three additional in the periphery) are found in iden-
tical positions in the ternary complexes of this study and
the ternary complex structure published by Allendorph et
al. [43] although the crystallization conditions differ sig-
nificantly. This corroborates our hypothesis that interface
water molecules play an important role in the ligand-type
I receptor recognition possibly by generating a major part
of the structural plasticity of BMP-2 [48]. In summary,
despite the reorientation of BMPR-IA upon recruitment of
the type II receptor ectodomain, the binding epitope of
the type I receptor remains unaltered.
The ligand-type II receptor core interface is predominantly 
hydrophobic
The β-strands 3, 4 and 6 of ActR-IIB together with β6 and
β7 of BMP-2 form the major part of the binding interface
(Fig. 4a). A part of the loop of finger 2 of BMP-2 also con-
tacts ActR-IIB. In total, 19 residues of BMP-2 and 17 resi-
dues of ActR-IIB (Fig. 4b,c) contribute significantly to the
interface. Remarkably, in comparison with the ternary
complex of BMP-2 bound to BMPR-IA and ActR-II the
backbone conformation of the bound ActR-IIB and ActR-
II is highly similar, exhibiting an r.m.s. deviation for the
Cα-atoms of 0.6 Å (a global fit on all 558 Cα-atoms yields
an r.m.s. deviation of 1.13 Å). The backbone as well as the
sidechain conformation of residues in the β2β3 loop (also
referred as M-loop) of ActR-IIB and ActR-II, which is pos-
sibly generating ligand specificity, are almost identical in
all BMP-2 ligand-receptor ternary complexes.
The type II receptor binding site of BMP-2 exhibits a con-
vex shape with no deep pockets and is predominantly
hydrophobic (Fig. 4b). The hydrophobic amino acids are
in the center and surrounded by a ring of polar and
charged residues. The core interface residue of ActR-IIB,
i.e. Trp60, Tyr42 Leu61, Lys56, V55, and Val81, exhibit
large accessible surface areas in the unbound state, which
become buried by 60 to 100% upon complex formation
(Fig. 4b,c). The knuckle epitope of BMP-2 has a comple-
mentary hydrophobic surface with a horseshoe-like form
(Fig. 4b). The shape results from the central Ser88, which
is embedded, in the hydrophobic patch together with the
peripheral polar side chain of Asn102.
In the complex Trp60 of ActR-IIB extends into a shallow
pocket formed by Ala34, Pro35, Ser88, Leu90 and Leu100
of BMP-2 (Fig. 4b,c), all of which were identified as
important determinants for type II receptor binding
before [28]. The hydrophobic area around Trp60 meas-
ures 12 by 12 Å and is devoid of any water molecules. To
test the hypothesis that the majority of the binding free
energy originates from hydrophobic interactions, we have
used isothermal titration calorimetry. The enthalpy ΔH,
which is a measure for polar interactions, is rather small
for the BMP-2:ActR-IIBECD interaction (14 kcal mol-1 atBMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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25°C), suggesting that polar interactions play a minor
role for the binding affinity of BMP-2 to type II receptors.
In comparison, the enthalpy for the interaction of BMP-2
and BMPR-IAECD is more than twice as large (-36 kcal mol-
1). Another indication is in the temperature dependency
of the enthalpy, the heat capacity change ΔCp  which
should have a negative value for interactions driven by the
burial of hydrophobic interfaces [49]. As a matter of fact a
BMP-2 type I receptor interface Figure 3
BMP-2 type I receptor interface. (a) The tilt angle of BMPR-IA bound to BMP-2 changes upon binding of the type II recep-
tor ActR-IIB. A superposition of the structures of BMP-2:(BMPR-IAECD)2 (blue, PDB entry 1REW), the ternary complex (1:1:1) 
of wildtype BMP-2:BMPR-IAECD:ActR-IIBECD (green) and the ternary complex (1:2:2) of BMP-2L100K/N102D:(BMPR-
IAECD)2:(ActR-IIBECD)2 (red) is shown. The comparison of both assemblies reveals that the rearrangement is not due to the 
mutations introduced in BMP-2L100K/N102D. (b) A change in the backbone conformation of residues 86 to 88, and 100 to 
105 located in the finger 2 of BMP-2 is the possible cause for the tilt angle change. The type I ligand-receptor interfaces of the 
ternary (1:1:1) (c) and (1:2:2) (d) BMP-2/receptor complexes are structurally almost identical differing only in very few H-
bonds that are located at the solvent accessible surface.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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BMP-2 type II receptor interface Figure 4
BMP-2 type II receptor interface. (a) Location of the type II ligand/receptor binding epitopes on wildtype BMP-2 (left) and 
ActR-IIBECD(right). For designation of β-strands and finger-like structures see [62], the contact residues are marked in grey. 
(b) Surface representation of the type II ligand/receptor binding epitopes in the ''open book'' view. The surface of BMP-2 (left) 
is color coded by amino acid properties as follows: hydrophobic amino acids (A, F, G, I, L, M, P, V, W, Y) are shown in white/
grey, polar residues in bright/dark green (H, N, Q, S, T), acidic residues in orange/red (D, E) and positively charged amino acids 
(K, R) in cyan/blue. Darker colors mark the contact interface. The surface of ActR-IIBECD (right) is color coded identically. (c) 
Contact scheme of the wildtype BMP-2:ActR-IIBECD interaction. Intermolecular van der Waals contacts (cutoff 4.5 Å) are 
marked by lines, H-bonds are shown in red. Contacts involving hydrophobic residues of BMP-2 are shown in the left panel, 
interactions involving polar residues of BMP-2 are on the right. The surface area (Å2) buried upon complex formation is indi-
cated by small numbers.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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rather large negative value of -496 cal mol-1 K-1 was deter-
mined for the ΔCp (see Additional file 5) of the BMP-
2:ActR-IIBECD  interaction being consistent with the
hypothesis that hydrophobic forces drive the binding of
the type II receptors to BMP-2.
Analysis of the contact between ActR-IIBECD and wildtype
BMP-2 indeed yields only five intermolecular polar
bonds, one ion pair and four H-bonds (see Additional file
4, Fig. 4c). It is interesting to note that in the ternary com-
plex of BMP-2 bound to BMPR-IA and ActR-II just two H-
bonds, between BMP-2 Ser88 Oγ and ActR-II Leu61 NH
and between BMP-2 Glu109 Oε2 and ActR-II Lys37 Nζ,
are observed [43]. This observation suggests that for low-
affinity binding polar bonds contribute only marginal to
the overall binding energy. The H-bond between BMP-2
Ser88 Oγ and ActR-IIB Leu61 NH is in the center of the
otherwise hydrophobic epitope, whereas the other polar
bonds reside at the periphery. As noted before [43], the
contact residues involved in the type II receptor interac-
tions are very similar among BMPs and activins. The
horseshoe-like hydrophobic core of the knuckle epitope
of BMP-2, BMP-7 and Act-A contains identical or isofunc-
tional residues at equivalent positions (Fig. 5a). Remarka-
bly, the polar Ser88 at the center of the epitope is highly
conserved. Pronounced differences exist at the periphery
of the epitope (e.g. residues at positions corresponding to
residues 36, 85, 96, 97, 100, 102, 104, and 109 in BMP-
2). In particular, the residues at the polar opening of the
hydrophobic core and juxtaposed to conserved Ser88 vary
among the BMPs and Act-A (Fig. 5a).
A comparison of the receptors ActR-IIB and ActR-II shows
that the same amino acid types form the hydrophobic
core around Trp60 (Fig. 5b) with 56% of the hydrophobic
interface residues being identical. Most significantly, the
central H-bond between receptor Leu61 (amide) and lig-
and Ser88 (hydroxyl group) seems to be formed in all
BMP/Activin receptor complexes analyzed so far [40-43],
irrespective whether ActR-IIB or ActR-II is present (Fig. 5c–
e). The structural data indicate that activin type II receptor
binding at the knuckle epitope is astonishingly similar in
the BMPs and activins. Thus, the few side chains that differ
in the ligand proteins must generate the differences
observed in the relative binding affinities of the various
receptor-ligand pairs.
A hydrophobic hot spot dominates the promiscuous ligand-
type II receptor interaction
In order to define the binding determinants of ActR-IIB
for the BMPs and Act-A an alanine scanning analysis was
performed. Interaction analysis by plasmon resonance
spectroscopy employing immobilized ligands confirmed
that ActR-IIBECD binds Act-A with high affinity, whereas
binding to BMP-2 and BMP-7 had a 50 to 100-fold lower
affinity (Table 1). In the setup used in this study the
apparent KD values were higher by at least two orders of
magnitude than those previously determined for ActR-II/
IIB using the same technique but with immobilized recep-
tors [28,40,42] or radioligand binding to receptors in
whole cells [50]. A possible explanation is due to the fact
that two immobilized receptors may bind together to a
single dimeric ligand thereby increasing the apparent
affinity by avidity effects. This avidity effect has been
quantified in the BMP system in part previously and
seems to be highly dependent on the setup conditions
[40]. An immobilized ligand, however, binds two single
receptor ectodomains independently thereby resulting in
the lower affinity of a 1:1 interaction [51], but due to the
absence of any avidity effects yields more comparable
data. Nevertheless the term apparent KD  was used
throughout since the absolute values of the KD  still
depend on the evaluation routine, immobilization level,
and also on the method used for immobilization. This
might explain the higher values reported for the affinities
of the Act-A:ActR-II [40] and Act-A:ActR-IIB [42] interac-
tion reported previously. When the low-affinity binding
to BMP-2 is analyzed, the by far most disruptive mutation
exists in the ActR-IIB variant W60A (Table 1). A consider-
able loss of affinity is also observed for the variant Y42A.
Substitution of other hydrophobic residues by alanine
yielded variants with a less than 10-fold loss in binding
affinity for BMP-2. Substitutions at the polar residues all
have no (Glu34, Gln80) or only a minor impact (Lys37,
Arg46, Lys56, Asp63) on binding affinity for BMP-2.
Therefore the functional binding epitope of ActR-IIB for
BMP-2 seems to be dominated by Trp60 and to a lesser
extent by Tyr42, which together form the hydrophobic
core of the epitope. The surrounding hydrophobic side
chains seem to be binding determinants of secondary
importance. Four of the polar side chains (Glu34, Lys37,
Arg46, and Gln80) forming ion pairs or H-bonds with
BMP-2 (Fig. 4c) could be removed without major effect on
affinity. Remarkably, a L61P variant has the same affinity
for BMP-2 as L61A, even though the central hydrogen
bond involving the amide of L61 is blocked by the proline
substitution (Table 1). Therefore, the conserved central H-
bond is also non-functional (silent) in the low-affinity
BMP-2:ActR-IIB interaction. Together these data indicate
that binding free energy of low-affinity BMP-2:ActR-IIB
interaction is derived almost exclusively from hydropho-
bic interactions.
From the functional data the binding mechanism of ActR-
IIB to BMP-2 or BMP-7 seems comparable (Table 1). The
main binding determinant for BMP-7 is also Trp60 fol-
lowed by Tyr42. Several variants show a similar loss in
affinity for BMP-2 and BMP-7. Small differences exist for
the variants R46A and L61P. A significant difference is in
the interaction of both BMPs with Lys37 of ActR-IIB. TheBMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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Binding epitopes of BMPs and activin for interaction with activin receptors are very similar Figure 5
Binding epitopes of BMPs and activin for interaction with activin receptors are very similar. (a) Structure based 
sequence alignment for the regions of BMP-2, BMP-7 and Act-A building the knuckle epitope. The putative contact residues 
based on the BMP-2:ActR-IIB interaction are color coded according to Fig. 4b. Asterisks mark the amino acid positions chosen 
for „domain swapping" between BMP-2 and Act-A, the conserved Ser is indicated by a triangle. (b) Sequence alignment of the 
extracellular domain of ActR-IIB, ActR-II and BMPR-II, the residues contributing to the binding epitope (based on the BMP-
2:ActR-IIB interface of this study) are color coded on amino acid properties as in Fig. 4b. (c-e) Comparison of the structural 
environment around the central H-bond in the complexes of (c) wildtype BMP-2:BMPR-IA:ActR-IIB, (d) Act-A:ActR-IIB (PDB 
entry 1S4Y, [42]) and (e) BMP-7:ActR-II (PDB entry 1LX5, [40]).BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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ActR-IIB variant K37A binds with increased affinity to
BMP-7, whereas the affinity of K37A for BMP-2 drops.
Modeling studies suggested that Lys37 of ActR-IIB might
be one of the key residues for generating ligand specificity
among different BMP members [43]. These results
obtained for BMP-7 support the hypothesis that the low-
affinity binding to BMPs is determined by a hydrophobic
ActR-IIB binding epitope employing virtually the same
hydrophobic binding determinants.
The functional epitope of ActR-IIB for high-affinity inter-
action with Act-A uses the same hydrophobic main bind-
ing determinant as for binding of the BMPs. As compiled
in table 1, Trp60 and Tyr42 are also crucial for binding of
Act-A. The minor hydrophobic and polar determinants
are of comparable importance for binding to BMPs and
Act-A. Tyr42 and Leu61 seem to contribute somewhat
more to Act-A than to BMP binding, whereas Lys37 and
Arg46 play a likewise lesser role in Act-A binding. These
small differences might contribute to ligand discrimina-
tion to some extent. However, it is probably safe to con-
clude that an increment in binding free energy
corresponding to a low-affinity interaction is the same in
binding of BMPs and Act-A, and likely the determinants
for this low-affinity interaction are the same for these lig-
ands. But in addition a further hot spot of binding is
present.
A clear and probably crucial distinction of the functional
Act-A binding epitope is the importance of the Leu61
amide group as revealed by comparison of the L61A and
L61P variants (Table 1). The removal of the amide proton
by the proline substitution leads to a 100-fold higher
decrease in binding affinity (2500-fold) than the loss of
the Leu61 side chain in the L61A variant (24-fold). As
mentioned above BMP-2 and BMP-7 binding affinity is
similar for both variants. This finding strongly suggests
that the central conserved hydrogen bond, which is inac-
tive/silent in BMP-2 and BMP-7 interaction, is active in
the interaction with Act-A (Fig. 5c–e). This "switchable"
H-bond seems to be responsible for the high-affinity
binding of Act-A.
In conclusion, the determinant for the high-affinity bind-
ing of Act-A seems to reside in the H-bond provided by the
Leu61 amide proton (which is removed in the variant
L61P), whereas this central H-bond interaction does not
play an important role for low-affinity interactions with
the ligands BMP-2 and BMP-7.
A switch in BMP-2 for low- and high-affinity binding of 
ActR-IIB
To investigate the mechanism of the ligand-specific prop-
erties of this central H-bond in more detail, residues in the
BMP-2 knuckle epitope were subjected to mutational
analysis (Table 2). The conserved Ser88 (Oγ), the H-bond
acceptor, is surrounded by residues differing between
BMP-2, BMP-7 and Act-A (Fig. 5a). We therefore per-
formed a partial "domain swapping" by exchanging resi-
dues of BMP-2 at the positions 85, 86, 100, and 102 for
those of Act-A (Table 2). BMP-2 Ser85 and Ala86 are not
critical for ActR-IIB binding as seen by the KD values of the
Table 1: Mutational analysis of the ActR-IIB interface (Biosensor analysis)
Ligand proteins (immobilized)
ActR-IIBECD BMP-2a BMP-7 Act-A
rel. KD (app. KD in nM)
wildtype 1 (7700) 1 (3600) 1 (65)
E34A 1 1.8 1
K37A 6.1 0.3 0.7
Y42A 61 49 290
R46A 8.4 3.3 2.9
K56A 11 14 2.7
W60A n.bb n.b. n.b.
L61A 6.4 6.4 24
L61P 7.9 19 2510
D63A 9.6 6.7 8.6
Q80A 1.3 1 1.1
F83Ac n.b. n.b. n.b.
a) For these measurements glycosylated BMP-2 expressed in CHO cells was used.
b) Binding is below detection limit (KD > 1 mM.)
c) This variant might be not native and exhibits an altered electrophoretical mobility in SDS-PAGE under non-reducing conditions.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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respective single and double mutants. The effect of the
BMP-2 mutation S85R on the binding to ActR-II has been
analyzed previously [43]. The authors report an increase
in binding affinity, i.e. 2-fold. The differences in the bind-
ing affinities might be due to the different experimental
setup.
The side chains at positions 100 and 102 exert a decisive
role in affinity determination. BMP-2 variants containing
the substitution L100K show a six to 20-fold increase in
binding affinity for ActR-IIB. The BMP-2 double variant
L100K/N102D binds to ActR-IIB with an affinity (KD ~
140 nM) almost as high as for the interaction of Act-A
with ActR-IIB (KD ~ 60 nM) (Table 2). The single mutation
N102D in BMP-2 is deleterious but in combination with
the exchange L100 K the affinity for ActR-IIB is further
increased. The exchange of these two residues of BMP-2
therefore converts the low- into a high-affinity binding
epitope and the lysine side chain seems to be the key
determinant for this transformation.
A previous mutational analysis of Act-A has shown that a
positively charged residue at position 102 (equivalent to
position 100 in BMP-2) is required for activin receptor
binding [52]. This indicates that this lysine is also essen-
tial for high-affinity binding of Act-A. From structure-/
function analyses of the Act-A:ActR-IIB interaction it has
been proposed that an intermolecular H-bond between
the Lys amine group and the backbone carbonyl of Cys59
of ActR-IIB contributes to high-affinity binding (trans
effect) [41], although the geometrical parameters of this
H-bond are close to the exclusion criteria (Fig. 6a). A sim-
ilar mechanism has been also proposed from the structure
analysis of BMP-2 bound to BMPR-IA and ActR-II [43]. A
comparison of the binding affinities of ActR-IIB variants
to Act-A and BMP-2 already suggested that the main dif-
ference is, however, in the strength of the central con-
served H-bond between Ser88 Oγ (BMP-2) and Leu61
amide (ActR-IIB). Confirming this, our structure of the
ternary complex (1:2:2) comprising BMP-2L100K/N102D
shows no additional intermolecular H-bond between the
lysine side chain and Cys59 of ActR-IIB (Fig. 6b).
Instead a double mutant cycle (Table 3) now reveals that
the strength of the H-bond between Ser88 Oγ (BMP-2)
and Leu61 amide (ActR-IIB) can be modulated through
the presence of a Lys and an Asp residue at position 100
and 102. Disruption of the central conserved H-bond, i.e.
by the ActR-IIB variant L61P, in the environment of
Lys100 and Asp102 leads to a drastic reduction in binding
affinity to BMP-2 similar to that observed for the interac-
tion Act-A:ActR-IIBL61P. Comparing the affinities of the
ActR-IIB variants L61P and L61A to wildtype BMP-2
shows no difference, indicating that, by contrast, in the
wildtype environment the central H-bond does not con-
tribute to the binding free energy (Table 3, Fig. 6d,e).
The residues Lys100 and Asp102 are located directly
above the intermolecular H-bond between BMP-2 Ser88
Oγ and ActR-IIB Leu61 amide at the opening of the horse-
shoe-like hydrophobic core of the epitope (Figs. 4b and
6a,b). In the structures of the Act-A:ActR-IIBECD [41] and
the ternary complex (1:2:2) of BMP-2L100K/N102D the
Lys and Asp residues form a stable intramolecular salt
bridge (Fig. 6a,b). Accordingly, Lys100 and Asp102 (in
BMP-2L100K/N102D) exhibit low temperature factors
indicating that both residues are quite immobile. In the
structure of the ternary complex (1:1:1) comprising
wildtype BMP-2 the temperature factors of the equivalent
residues Leu100 and Asn102 are higher than for nearby
residues indicating increased flexibility. The "rigid lid"
centered above the conserved H-bond between BMP-2
Table 2: Type II receptor specificity of wildtype BMP-2 and variants (Biosensor analysis)
Receptor ectodomain proteins
BMP-2 (immobilized) ActR-IIB ActR-II BMPR-II
rel. KD (app. KD in nM)
wildtypea 1 (2700) 1 (5500) 1 (24000)
S85R 1.3 0.85 0.12
A86P 2.6 1.5 0.50
S85R/A86P 1.4 1.3 0.19
L100K 0.15 0.84 1.3
N102D 7.8 3.6 0.96
L100K/N102D 0.05 0.29 0.92
Act-Ab 0.02 (60) 0.04 (230) 0.36 (8700)
BMP-7b 1 (2800) 0.09 (430) 1.3 (32000)
a) BMP-2 variants were expressed in E. coli. Note, that the wildtype BMP-2 expressed in E. coli has a higher affinity to ActR-IIB than the glycosylated 
BMP-2 produced in CHO cells (see Table 1)
b) the relative binding constant (normalized to E. coli BMP-2 as a reference) of BMP-7 and Act-A are given for comparison.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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Ser88 Oγ and ActR-IIB Leu61 amide might provide an
effective shielding from solvent access thereby enhancing
the strength of this particular H-bond (Fig. 6a–c). By thus
modulating the energy contribution of an existing interac-
tion (cis effect) rather than adding a new (trans effect) one
achieves the switch from low- to high-affinity.
Specificity in the BMP-2 type II receptor epitope
Individual and combined mutations at BMP-2 position
85, 86, 100 and 102 influence binding of unalike type II
receptors (Table 2) suggesting that these residues deter-
mine binding specificity of BMP-2 for ActR-II, ActR-IIB
and BMPR-II. The exchange of Leu100 of BMP-2 to lysine
Mechanism for affinity switch in BMP-2 L100K/N102D Figure 6
Mechanism for affinity switch in BMP-2 L100K/N102D. H-bond network around the conserved serine residue in Act-A 
(a), the BMP-2 variant L100K/N102D with increased ActR-IIB affinity (b) and wildtype BMP-2 (c). The conserved central H-
bond between Ser88 Oγ (Ser90 in Act-A) and Leu61 amide of ActR-IIB is shown as green thick stippled line. The intramolecu-
lar H-bond network comprising Lys100, Asp102, Ser88 (Lys102, Asp104 and Ser90 in Act-A) and a nearby structurally con-
served water molecule is indicated by stippled lines in magenta. The putative intermolecular H-bond between Lys102 of Act-A 
and Cys59 backbone carbonyl of ActR-IIB in the structure of the complex Act-A:ActR-IIBECD (PDB entry 1S4Y, [42]) is indi-
cated by a thin line (a), as this H-bond is only present on one half of the dimeric complex and its geometrical parameters are 
close to exclusion cutoff criteria. A comparison of the position of the structurally conserved water molecule in the three struc-
tures shows that in wildtype BMP-2 (c) this solvent molecule is located directly above the central H-bond indicating direct 
accessibility of the H-bond by solvent. (d, e) Surface representation of ActR-IIB color coded by the contribution (ΔΔG in kJ 
mol-1) of each residue side chain to the binding free energy for (d) wildtype BMP-2 and (e) Act-A as measured by alanine scan-
ning mutational analysis (see Table 1). For residue L61 the exchange to proline was used to point out the influence of the cen-
tral conserved H-bond. The ΔΔG values are given in kJ mol-1. Dark red color marks hot spots of binding with an energy 
contribution of more than 15 kJ mol-1. Residues in yellow contribute only little; energy contribution of residues marked in blue 
is considered insignificant.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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specifically increases the binding affinity for ActR-IIB,
whereas binding to ActR-II and BMPR-II is basically unaf-
fected. The double variant L100K/N102D shows a large
increase in affinity for ActR-IIB, in addition the affinity for
ActR-II is moderately increased (threefold), but binding to
BMPR-II remains unaltered. Mutating residues Ala86 and
in particular Ser85 in BMP-2 results in variants that
exhibit an increased binding affinity exclusively for
BMPR-II whereas binding to the activin type II receptors is
either unaffected or even decreased. The specific effects of
these mutations indicate that the BMP-2 knuckle epitope
comprises single residues specifying relative affinities and
therefore specificity for the interaction with type II recep-
tors ActR-IIB, ActR-II and BMPR-II (Fig. 5a,b).
In order to understand if the change in type II receptor
specificity of these BMP-2 variants is reflected in their bio-
logical activity, the variants were tested for their capabili-
ties to induce alkaline phosphatase (ALP) expression in
the myoblast cell line C2C12 (Fig. 7). The C2C12 cells
express the type II receptors ActR-II and BMPR-II but not
ActR-IIB [53]. The two BMP-2 variants S85R/A86P and
L100K/N102D have a three to four-fold lower EC50 value
than wildtype BMP-2 corresponding to a higher biological
activity (Fig. 7a). These results seem to reflect the three to
five-fold higher affinity of the double mutants for the
ActR-II, respectively the BMPR-II receptor. In contrast,
when the single mutant L100K is analyzed in parallel with
wildtype BMP-2 the EC50 is the same (Fig. 7b). This might
be expected since the BMP-2 variant L100K has an unal-
tered affinity for ActR-II and BMPR-II and the specifically
increased affinity of L100K for ActR-IIB is biologically not
relevant in this specific cell type. In summary, these data
strongly suggest that the specific alterations in the mutant
BMP-2 can be biologically relevant.
Discussion
ActR-IIB is one of three type II receptors known to interact
with BMP-2 [15]. The ectodomains of all three type II
receptors bind with low affinity to this ligand (Table 2).
BMPR-II has the lowest affinity although in many cells it
is the prototypic type II receptor for BMP-2. The affinity of
ActR-IIB, the strongest BMP-2 binder, is about 10-fold
higher. In how far these differences in low-affinity type II
binding are important for BMP-2 signaling is unknown.
The increase in the biological activities observed for BMP-
2 variants in our study suggests that such small differences
might be of functional relevance.
As shown by cross-linking experiments in whole cells,
low-affinity type II receptors alone do not bind or bind
only weakly to solute BMP-2 [36,54,55]. On the other
hand BMPR-IA, the high-affinity receptor of BMP-2, is effi-
ciently cross-linked when present alone, and in its pres-
ence cross-linking of the type II receptor proceeds
efficiently [54,55]. The BMPR-IA ectodomain binds BMP-
2 in our experimental setup with a dissociation constant
of 10 to 20 nM. This affinity is 100 to 200-fold higher than
that of the type II chains. On the basis of this large differ-
ence in the relative affinities of the type I and type II recep-
tors a 2-step assembly mode of the ternary complex can be
postulated, where solute BMP-2 binds first to the high-
affinity BMPR-IA receptor and subsequently in the mem-
brane the binary BMP-2/type I receptor complex can asso-
ciate with the type II receptor [48].
The affinity profile of Act-A for the type II ectodomains is
completely different from BMP-2. In the present experi-
ments the apparent KD of Act-A for ActR-IIB is about 60
nM (Act-A to ActR-II KD ~ 250 nM), typical for a high-
affinity interaction. In contrast BMPR-IIECD is bound by
Act-A with low affinity (KD ~ 10 μM) resembling the inter-
action with BMP-2. The type I activin receptor ActR-IB by
itself has an exceedingly low affinity for Act-A [14]. Chem-
ical cross-linking in the membrane is therefore only pos-
sible in the presence of the high-affinity ActR-II/B
receptors [56]. Consequently, the assembly of the ternary
activin receptor complex differs in crucial aspects from
that of the BMP-2 receptor. Solute Act-A binds first to its
high-affinity ActR-II/B receptors before the low-affinity
ActR-IB receptor is recruited into the complex in the mem-
brane [56]. As a consequence the type II activin receptors
play different roles and are involved in different assembly
modes during BMP-2 versus activin receptor activation. In
Table 3: Double mutant cycle of BMP-2 and ActR-IIBECD (Biosensor analysis)
Receptor ectodomain proteins
BMP-2a (immobilized) ActR-IIB ActR-IIBL61A ActR-IIBL61P
app. KD in Nm
wildtype 2700 42000 76000
L100K/N102D 140 14000 160000
Act-Ab 60 2000 180000
a) BMP-2 variants were expressed in E. coli.
b) the apparent binding constant of Act-A is shown for comparison.BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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this context BMPR-II is a special case. It likely cannot sig-
nal with Act-A, since it has only a low affinity for this lig-
and and a high-affinity type I chain is unknown. This
generally low affinity of BMPR-II for BMPs and activin
possibly explains why cytoplasmatically truncated BMPR-
II exerts a dominant negative effect on BMP but not on
activin signaling [57]. The truncated BMPR-II can com-
pete with the low-affinity interaction of type II receptors
and BMP-2 but not with the high-affinity interaction of
ActR-II/B and activin.
The ectodomains of the ActR-II and ActR-IIB share 44%
sequence identity (Fig. 7b). The affinities of BMP-2 for the
two isoforms are similar (see Table 2, [40]). It is therefore
interesting to compare the interface of BMP-2 for ActR-IIB
(this study) and ActR-II [43]. The hydrophobic core
around Trp60 (ActR-IIB numbering) is remarkably con-
served. Only residues Tyr42 and Tyr13 are replaced by
phenylalanine residues in ActR-II, however since both
tyrosine residues are no involved in H-bonds the replace-
ment should be without affect for the binding affinity.
Polar bonds at the periphery of the epitopes are different
supporting the conclusion already drawn from the muta-
tional analysis of ActR-IIB that they are not important for
binding affinity. Only the central H-bond connecting
BMP-2 Ser88 Oγ and Leu61 amide also exists in the com-
plex with ActR-II. Since a BMP-2 S88A variant exhibits
only a small decrease in binding affinity for ActR-II [28] it
can be assumed that this H-bond is silent or very weak as
in the complex of BMP-2 with ActR-IIB. In this context it
is intriguing that the BMP-2 variants L100K and L100K/
N102D have in comparison to ActR-IIB only a small effect
on binding affinity for ActR-II. In particular the double
variant L100K/N102D conferring high-affinity binding to
ActR-IIB has a six-fold lower effect on ActR-II binding,
while the single variant L100K shows no increase in affin-
ity for ActR-II at all (Table 2). The KD value for the interac-
tion between ActR-II and BMP-2 L100K has been reported
before [43] to be five to eight-fold lower than for wildtype
BMP-2. The reason for the discrepancy to the present
results is as yet unclear. BMP-2 L100K/N102D has not
been structurally analyzed in complex with ActR-II so far.
Possibly, the intramolecular hydrophobic lid formed by
Lys-Asp pair is less efficient in complex with ActR-II. Con-
sidering the identical side chain composition at the core
of the receptor epitopes it would be surprising, however,
if here an intermolecular H-bond between Lys102 of the
BMP-2 variant and the backbone carbonyl of ActR-II
Cys59, which is not observed in the complex with ActR-
IIB, would contribute to binding affinity [43].
Previously, BMP-2 mutants have been generated, which
function as BMP antagonists either due to disruption of
the knuckle epitope [28] or as Noggin-blocker due to inac-
tivation of the wrist epitope [48]. Now new BMP-2 vari-
ants could be obtained with increased biological activity
resulting from improved binding to ActR-II (L100K/
N102D) or BMPR-II (S85R/A86P) (Table 2). It will be
interesting to study if the "superagonist" activity of these
mutant proteins will be retained in vivo, e.g. in an ectopic
Biological activities of specificity-altered BMP-2 variants Figure 7
Biological activities of specificity-altered BMP-2 variants. (a) The BMP variants L100K/N102D (red) and S85R/A86P 
(green) exhibit a two- to three-fold lower EC50 value for ALP induction as wildtype BMP-2. The increased biological activity 
correlates with the increased affinity for ActR-IIB/ActR-II (L100K/N102D) or BMPR-II (S85R/A86P). (b) The single variant 
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bone formation assay or during healing of a critical size
bone defect. BMP-2 L100K/N102D may also function as
an ActR-IIB blocker, even though its affinity for this recep-
tor is still not as high as that of Act-A (Table 2) or of GDF-
8/-11 (W. Sebald, unpublished). However, it is unclear
whether BMP-2 variants can interact with the type I recep-
tor ActR-IB to some extent when strongly bound to ActR-
IIB. The results of the present structure/function analysis
of ActR-IIB might give some clues how relative affinity/
specificity to certain ligands can be mutationally altered
and manipulated. This might become useful for the
design of receptor ectodomain constructs, which can spe-
cifically inhibit certain BMPs, GDFs, activins, or other lig-
ands of the TGF-β superfamily.
Conclusion
In this study we present a detailed structure-function anal-
ysis of the interaction of BMP-2 – a prototypic ligand of
the TGF-β superfamily – with its type II receptor ActR-IIB.
In previous work the determinants for specificity and
affinity in type I BMPR-IA and BMPR-IB receptor interac-
tion have been analyzed [32,33]. Now new crystal struc-
tures of ternary complexes comprising BMPR-IA and ActR-
IIB ectodomains and either wildtype BMP-2 or a BMP-2
variant with enhanced affinity for ActR-IIB have been elu-
cidated at high resolution. On the basis of the structural
information a mutational analysis of ActR-IIB and the
interacting BMP-2 knuckle epitope has been performed in
order to investigate possible interactions between
epitopes as well as determinants for specificity and affinity
in type II receptor interaction, in particular with the dual-
specificity receptor ActR-IIB. The results reveal a molecular
basis for understanding differences in BMP-2, BMP-7 and
Act-A signaling. In addition the molecular mechanisms
for high- and low-affinity binding to the ActR-IIB receptor
have been clarified. The present results will possibly help
to design ligand and receptor mutant proteins that can be
used to target diseases caused by dysregulation of BMP or
activin signaling.
Methods
Expression and purification of recombinant proteins
E. coli derived BMP-2 proteins and the receptor ectodo-
main proteins of BMPR-IA, ActR-II and BMPR-II were
expressed and purified as described earlier [28]. The ActR-
IIBECD  was expressed as thioredoxin-fusion similar to
BMPR-IAECD in OrigamiB (DE3) (Novagen) cells. Cells
were harvested and lysed by sonication. The fusion pro-
tein was isolated from the supernatant by Ni2+-IMAC
chromatography, cleaved with 0.5 U thrombin per mg
fusion protein (Sigma) and the products subsequently
purified by anion exchange chromatography (TMAE,
Merck). ActR-IIBECD was finally purified by reversed phase
HPLC using a C4 column (Vydac). BMP-2 or ActR-IIBECD
variants were constructed by site directed mutagenesis
using the QuikChange methodology (Stratagene).
For acquisition of a MAD dataset using Se-Met derivatives,
a triple mutant variant of BMPR-IAECD  (F35M, L73M,
L95M) was generated. Binding properties to BMP-2 were
unaltered as tested by interaction analysis. The variant and
wildtype BMP-2 were expressed in M9 minimal medium
supplemented with 50 mg L-1 DL-Se-Met (Sigma) using
the Met-auxotroph E. coli strain B834(DE3) (Novagen).
Crystallization of the ternary ligand-receptor complex
The ternary complexes consisting of BMP-2 or BMP-2
L100K/N102D bound to BMPR-IAECD  and ActR-IIBECD
were prepared by a stepwise procedure. First the binary
BMP-2:BMPR-IAECD complexes were formed and purified
as described [58]. The purified binary complexes were
then mixed with a 2.2-fold molar excess of ActR-IIBECD in
HBS700 buffer (10 mM HEPES, 700 mM NaCl pH7.4) and
purified by gel filtration. Stoichiometry and homogeneity
of both complexes were analyzed by comparison to mix-
tures of the components with defined molar ratios using
SDS-PAGE and RP-HPLC. For crystallization the protein
complexes were concentrated to 15 mg ml-1. Crystals of
wildtype BMP-2: BMPR-IAECD:ActR-IIBECD were obtained
by hanging-drop vapor diffusion from 50% (v/v)
PPG400, 0.1 M Bis-Tris, pH5.8 at 21°C; for the complex
comprising the BMP-2 double variant crystallization was
achieved from 30% (w/v) PEG3350, 0.1 M Tris-HCl
pH8.8, 0.2 M ammonium acetate at 21°C. Crystals of a
final size of approximately 250 × 100 × 100 μm grew
within 8 days for both complexes.
Data acquisition and structure analysis
A MAD dataset of the ternary complex (1:1:1) was
acquired at three wavelengths (inflection, peak, remote)
with 360° rotation of the crystal (1° per frame) were
measured; a maximum resolution of 2.7 Å was obtained
by recording with 30 s exposure time per degree (beam-
line BL14.1 at BESSY, Protein Structure Factory, Ger-
many). The data were processed and integrated using
MOSFLM version 6.2.1, scaling was performed using
SCALA CCP4 version 4.2.1 (see Additional file 6). The
positions of the Selen-sites were determined using SHELX,
and refined using SOLVE version 2.06. RESOLVE and
ARP/WARP were used to automatically trace the electron
density and to yield an initial model. The structures of
BMP-2 monomer, BMPR-IA (both PDB 1REW, [48]) and
ActR-IIB (PDB 1NYS, [41]) were superimposed onto trac-
ing models to facilitate further model building. High-res-
olution native data for both ternary complexes were
acquired at 100 K on a home-source consisting of a Rigaku
MicroMax007, Osmic mirror optics and a Rigaku R-AXIS
IV++ detector. The exposure time for crystals of the ternary
complex (1:1:1) was 750 s per 0.5° rotation, crystals dif-BMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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fracted up to 1.75 Å. A complete dataset was obtained
from an 85° sweep, processing was performed using the
software CrystalClear (Rigaku Inc.) (Table 4). The initial
model of the MAD dataset was used to interpret and refine
the high-resolution data acquired for the ternary complex
(1:1:1). Data for the ternary complex (1:2:2) were also
acquired on the above described home source, the expo-
sure time was 300 s per 0.5°, crystals diffracted up to 1.8
Å. A complete dataset was acquired from a sweep of 129°.
The data were interpreted by molecular replacement using
the software Phaser employing the components of the ter-
nary complex (1:1:1) structure as search models.
Interaction analysis by surface plasmon resonance
The BIACORE2000 system was used for all biosensor exper-
iments. For measurement of ligand-specific binding capa-
bilities to different type II receptors a streptavidin-
modified biosensor CM5 was coated with biotinylated
BMP-2 (E. coli), BMP-2 (CHO cells, R&D Systems), BMP-
7 (CHO cells, R&D Systems), or Act-A (Sf9 cells) [59] to a
level of about 200 resonance units (1 RU = 1 pg mm-2).
Interaction with the type II receptors ActR-IIB, ActR-II [28]
and BMPR-II [28] was analyzed by recording sensorgrams
of the ligand-receptor interactions in HBS500 buffer (10
mM HEPES, pH7.4, 500 mM NaCl, 3.4 mM EDTA,
0.005% surfactant P20) using the receptor ectodomain
proteins as analyte. Surfaces were regenerated by per-
fusion for 2 min with 4 M MgCl2. All measurements were
corrected for non-specific interactions by subtracting a
control sensorgram recorded for flow cell 1. Apparent
binding constants (KD) were obtained from the dose
dependence of equilibrium binding using 1, 2, 3, 5, 10,
Table 4: Processing and refinement statistics
Data processing ternary complex 1:1:1 ternary complex 1:2:2
Space group P212121 P3221
Unit cell a = 64.1 Å, b = 65.4 Å, c = 114.1 Å
α = β = γ = 90°
a = b = 82.8 Å, c = 111.1 Å
α = β = 90°, γ = 120°
Resolution (Å) 20.0–1.81 Å (1.89–1.81 Å) 41.4–1.78 Å (1.84–1.78 Å)
Wavelength 1.5418 Å 1.5418 Å
Number of measured reflectionsc 134179 (11577) 282925 (18238)
Number of unique reflectionsc 43615 (4532) 42606 (4140)
Completeness 98.6 (93.7)% 99.6 (98.7)%
Multiplicity 2.9 (2.6) 6.6 (4.4)
Rsym for all reflections 5.5 (38.9)% 6.9 (51.4)%
<Intensity/σ> 9.6 (2.5) 12.6 (2.6)
Refinement statistics
Resolution 20–1.85 Å (1.92–1.85 Å) 40–1.92 Å (1.99–1.92 Å)
Rcryst 21.6 (36.7)% 22.8 (42.5)%
Rfree (Test set 5%) 22.5 (41.3)% 26.4 (42.5)%
r.m.s. deviation
Bonds 0.013 Å 0.006 Å
Angles 1.572° 1.249°
Torsion angles 1.084° 0.794°
Average B-Factor 38.7 Å2 52.4 Å2
Cross-validated sigma coordinate error 0.37 Å 0.45 Å
Solvent content 52.8% 60.9%
Procheck analysisd
Residues in most favored region 86.4% (291) 86.2% (219)
Residues in additional allowed region 11.9% (40) 13.0% (33)
Residues in generously allowed region 1.8% (6) 0.8% (2)
Residues in disallowed region 0% (0) 0% (0)
Statistical analysis for the highest resolution shell is shown in parentheses.
a) BMP-2:BMPR-IAECD:ActR-IIBECD complex
b) BMP-2L100K/N102D:(BMPR-IAECD)2:(ActR-IIBECD)2 complex
c) cut-off for reflections F > 0σ
d) number of residues is shown in parenthesesBMC Structural Biology 2007, 7:6 http://www.biomedcentral.com/1472-6807/7/6
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20, and 50 μM concentration of the receptor ectodomain
proteins. The mean standard deviations for all KD values
were < 20%.
Induction of alkaline phosphatase (ALP) expression
The mouse myoblast cell line C2C12 (ATCC, No. CRL-
1772) was cultured in DMEM:HamsF12 (1:1) medium
containing 5% fetal calf serum (FCS), and antibiotics (100
U ml-1 penicillin G and 100 μg ml-1 streptomycin). For
alkaline phosphatase induction (ALP) assays the cells
were serum starved (2% FCS) and exposed to ligands for
72 h in 96-well microplates [60]. After cell lysis ALP activ-
ity was measured by p-nitrophenylphosphate conversion
using an ELISA reader at 405 nm.
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